Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Friday announced the launch of AstraZeneca Direct, an online platform designed to provide eligible US patients with a simple, convenient way to access prescribed medications at a transparent cash price with home delivery.
The service targets patients with chronic conditions, including asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.
From October, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapagliflozin) can purchase these medications directly through the platform for up to 70% off the list price. FLUMIST (Influenza Vaccine Live, Intranasal) will also be available for home delivery.
Joris Silon, US country president at AstraZeneca, said that the platform complements AstraZeneca's existing patient support programmes and provides transparent pricing and convenient access.
The platform will be accessible at AstraZenecaDirect.com starting 1 October 2025.
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio